Investigating the effectiveness of intraovarian injection of platelet rich plasma on ovarian reserve in infertile women due to decreased ovarian reserve

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160722029027N14

Enrollment

Registered

2024-01-31

Start date

2024-01-01

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility.

Interventions

Intervention group: In all women included in the study and after collecting background information such as demographic characteristics and records related to previous pregnancy, on the first to third

Eligibility

Sex/Gender

Female

Age

18 Years to 42 Years

Inclusion criteria

Inclusion criteria: Women with infertility under 42 years old with diminished ovarian reserve as AMH<1ng/ml or AFC<5 Infertile women with poor ovarian response: with a history of retrieving less than 5 eggs in IVF

Exclusion criteria

Exclusion criteria: Infertility due to inflammation Endometriosis and PID Hyperandrogenism and PCO Anatomical disorder Anatomical disorder Platelet defects bleeding disorders

Design outcomes

Primary

Measure	Time frame
Reduced ovarian reserve: AMH serum level<1ng/ml or AFC<5 in women under 42 years of age. Timepoint: 2 months. Method of measurement: In all women included in the study, on the first to third day of menstruation under ultrasound (if there is no follicle above 10 mm and the thickness of the endometrium is below 5 mm and ovulation) and treatment with Pergoveris injectable gonadotropin twice a day, and when the growing follicle reaches 12-14 mm in size, GnRH antagonist (0.25 mg/day cetrotide) will be started subcutaneously. This injection will continue until the day of (ovitrelle (recombinant HCG) (250 micrograms) administration. When the dominant follicle reaches 18 mm, ovulation is induced using (ovitrelle (recombinant HCG (250 micrograms)) and transvaginal oocyte retrieval during 34 to 36 hours after the injection (ovitrelle (recombinant HCG (250 micrograms)) will be performed with ultrasound guidance. On the day of ovulation, after ovarian puncture, 3 cc of PRP injection will be performed. If the IVF cycle fails, on the third Menstrual cycle After checking the serum level of FSH, AMH and the presence of at least one AFC in the ultrasound, the patients are again included in the ovulation stimulation cycle.	—

Measure

Time frame

Reduced ovarian reserve: AMH serum level<1ng/ml or AFC<5 in women under 42 years of age. Timepoint: 2 months. Method of measurement: In all women included in the study, on the first to third day of menstruation under ultrasound (if there is no follicle above 10 mm and the thickness of the endometrium is below 5 mm and ovulation) and treatment with Pergoveris injectable gonadotropin twice a day, and when the growing follicle reaches 12-14 mm in size, GnRH antagonist (0.25 mg/day cetrotide) will be started subcutaneously. This injection will continue until the day of (ovitrelle (recombinant HCG) (250 micrograms) administration. When the dominant follicle reaches 18 mm, ovulation is induced using (ovitrelle (recombinant HCG (250 micrograms)) and transvaginal oocyte retrieval during 34 to 36 hours after the injection (ovitrelle (recombinant HCG (250 micrograms)) will be performed with ultrasound guidance. On the day of ovulation, after ovarian puncture, 3 cc of PRP injection will be performed. If the IVF cycle fails, on the third Menstrual cycle After checking the serum level of FSH, AMH and the presence of at least one AFC in the ultrasound, the patients are again included in the ovulation stimulation cycle.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Nazari

Shahid Beheshti University of Medical Sciences

nazari@sbmu.ac.ir+98 21 2243 9872

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026